Predictors of Ovarian Insufficiency in Young Breast Cancer Patients (POISE)

University of California San Diego

Status: Completed

Conditions: Breast Cancer; Ovarian Insufficiency; Ovarian Failure

Study type: Observational

Funder types: Other; NIH

Identifiers

NCT01197456

UCSD POISE

K23HD058799 (U.S. NIH Grant/Contract)

Details and patient eligibility

About

More than two million American women are breast cancer survivors. Approximately one-third of these women are premenopausal at diagnosis and face issues related to reproduction as they undergo cancer treatment. Ovarian function after breast cancer diagnosis has implications on breast cancer prognosis, choice of adjuvant therapy and reproductive issues such as desire for fertility or concerns about menopause. Therefore, tools to accurately predict ovarian function in breast cancer survivors could significantly impact physicians and patients in counseling, medical and surgical treatment choices, and consideration of fertility preservation options.

The goal of this proposal is to identify pre-chemotherapy hormonal, genetic and ovarian imaging markers that can predict ovarian failure and characterize the course of ovarian function after chemotherapy. The investigators plan to follow a group of young women from breast cancer diagnosis to five years after chemotherapy. The investigators will study the following risk factors: blood hormone levels that reflect ovarian function, genetic mutations that affect how individuals metabolize chemotherapy, and ovarian size and egg count by MRI and ultrasound. The investigators hypothesize that these biomarkers are related to risk of ovarian insufficiency singly. After examining these individual risk factors for ovarian failure, the investigators will put them together into an Ovarian Failure Clinical Predictive Index. This index will be a tool similar to the Gail Model that can be used to determine individual risk for ovarian failure. This tool would assist young breast cancer patients and their physicians in making treatment decisions that would impact cancer survival and reproduction.

Enrollment: 232 patients

Sex: Female

Ages: 18 to 45 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• New diagnosis of breast cancer (Stages 0-III)
• Age <=45
• Premenopausal (at least one menses over past year)
• Has a uterus and at least one ovary

Exclusion criteria

• Prior chemotherapy

Trial design

232 participants in 2 patient groups

Exposed/chemotherapy

Description:

Breast cancer patients who will undergo chemotherapy

Unexposed

Description:

Breast cancer patients who will not undergo chemotherapy